PARP Inhibitors and Myeloid Neoplasms: A Double-Edged Sword

SIMPLE SUMMARY: Poly(ADP-ribose) polymerase (PARP) inhibitors, which are medications approved to treat various solid tumors, including breast, prostate, ovarian, and prostate cancers, are being examined in hematological malignancies. This review summarizes the potential role of PARP inhibitors in th...

Descripción completa

Detalles Bibliográficos
Autores principales: Csizmar, Clifford M., Saliba, Antoine N., Swisher, Elizabeth M., Kaufmann, Scott H.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699275/
https://www.ncbi.nlm.nih.gov/pubmed/34945003
http://dx.doi.org/10.3390/cancers13246385

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8699275/
https://www.ncbi.nlm.nih.gov/pubmed/34945003
http://dx.doi.org/10.3390/cancers13246385

Ejemplares similares